

Express Mail Label No.: ED 798634993 US Attorney Docket No.: 100869-1P US



AWI

From the INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

1 7 MAR 2005 ASTRAZENECA Global Intellectual Property CODE DATE NTD NOTIFICATION OF TRANSMITTAL OF S-151 85 Södertälje THE INTERNATIONAL PRELIMINARY SUEDE REPORT ON PATENTABILITY (PCT Rule 71.1) ANKOM 15 MAR 2005 **GIPS** Date of mailing (day/month/year) 07.03.2005 DATA ENTERED Applicant's or agent's file reference FINAL IMPORTANT NOTIFICATION 100869-1 WO CHECK Priority date (day/month/year) International filing date (day/month/year) International application No. 20.03.2003 16.03.2004 PCT/GB2004/001132

- 1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary report on patentability and its annexes, if any, established on the international application.
- 2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
- 3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

ASTRAZENECA AB et al.

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed inventions is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the international preliminary examining authority:

European Patent Office - P.B. 5818 Patentiaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016 **Authorized Officer**

Cardenas, C

Tel. +31 70 340-3370



ATENT	COOPERATION	TREAT
AILINI	COOI ENAMEN	11167

ANKOM: 16 MAR 2005

CODE

DATE

NTD

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 100869-1 WO	OR FURTHER AC	TION	See Form PCT/IPEA/416			
International application No.	temational filing date (d	ay/month/year)	Priority date (day/month/yea	ar)		
PCT/GB2004/001132	5.03.2004		20.03.2003			
International Patent Classification (IPC) or national classification and IPC C07D413/14, C07F9/6558, A61K31/422, A61K31/675, A61P31/04						
Applicant ASTRAZENECA AB et al.						
This report is the international prelimi Authority under Article 35 and transm	itted to the applicant	according to Article 3	s International Preliminary l 3.	Examining		
2. This REPORT consists of a total of 6						
3. This report is also accompanied by A						
a. Sent to the applicant and to the						
sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).						
sheets which supersede e beyond the disclosure in t Supplemental Box.	sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box					
b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)), containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).						
4. This report contains indications relati	ng to the following ite	ems:				
☐ Box No. I Basis of the opinion	n					
☐ Box No. II Priority						
☑ Box No. III Non-establishment	of opinion with regar	rd to novelty, inventive	step and industrial applica	bility		
☐ Box No. IV Lack of unity of inv	ention					
	nt under Article 35(2 ns and explanations) with regard to novelt supporting such state	y, inventive step or industria ment	al		
☑ Box No. VI Certain documents	cited					
☐ Box No. VII Certain defects in t	he international appl	ication	•			
☐ Box No. VIII Certain observation	ns on the internationa	al application				
Date of submission of the demand		Date of completion of the	nis report			
22.09.2004		07.03.2005				
Name and mailing address of the international preliminary examining authority:	Authorized Officer		A STATE OF THE STA			
European Patent Office - P.B. 58 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 65 Fax: +31 70 340 - 3016	Allard, M Telephone No. +31 70	340-2002				





INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/GB2004/001132

	Box No. I	Basis of the report
١.	With regar	rd to the language , this report is based on the international application in the language in which it was as otherwise indicated under this item.
	which	eport is based on translations from the original language into the following language, is the language of a translation furnished for the purposes of: ernational search (under Rules 12.3 and 23.1(b)) blication of the international application (under Rule 12.4)
		ernational preliminary examination (under Rules 55.2 and/or 55.3)
2.	have beer	rd to the elements* of the international application, this report is based on (replacement sheets which in furnished to the receiving Office in response to an invitation under Article 14 are referred to in this "originally filed" and are not annexed to this report):
	Descriptio	n, Pages
	1-58	as originally filed
	Claims, N	ımbers
		as originally filed
	1-12	as diignany med
	□ a seq	uence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing
3.	☐ The a	amendments have resulted in the cancellation of:
		e description, pages
		e claims, Nos. e drawings, sheets/figs
		e drawings, sneetsings e sequence listing <i>(specify)</i> :
		ny table(s) related to sequence listing (specify):
4.	had not b Suppleme	report has been established as if (some of) the amendments annexed to this report and listed below een made, since they have been considered to go beyond the disclosure as filed, as indicated in the ental Box (Rule 70.2(c)).
	☐ th	e description, pages e claims, Nos. e drawings, sheets/figs
		e drawings, sneetsings e sequence listing (specify):
	□ ar	ny table(s) related to sequence listing (specify):
		the description and an old of these shoots may be marked "supported "



INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/GB2004/001132

		No. III Non-establishment o dicability	f opi	nion with regard to novelty, inventive step and industrial		
۱.	The obv	The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non- obvious), or to be industrially applicable have not been examined in respect of:				
		the entire international applicati	on,			
	⊠	claims Nos. 7 (in whole), 8, 9-1	2 (in	part)		
		because:		·		
	⊠	the said international applicatio not require an international pref	n, or imina	the said claims Nos. 8 relate to the following subject matter which does ary examination (specify):		
		see separate sheet				
		the description, claims or drawithat no meaningful opinion coul	ngs (ld be	indicate particular elements below) or said claims Nos. are so unclear formed (specify):		
		the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.				
	Ø	no international search report has been established for the said claims Nos. 7 (in whole), 9-12 (in part)				
		the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:				
		the written form	Ö	has not been furnished		
				does not comply with the standard		
		the computer readable form		has not been furnished		
				does not comply with the standard		
		the tables related to the nucleo not comply with the technical re	tide a equir	and/or amino acid sequence listing, if in computer readable form only, do ements provided for in Annex C-bis of the Administrative Instructions.		
		See separate sheet for further	detai	ls ·		



INTERNATIONAL PRELIMINARY REPORT **ON PATENTABILITY**

International application No. PCT/GB2004/001132

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial Box No. V applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-6, 8-12

No: Claims

Yes: Claims

No:

Claims 1-6, 8-12

Industrial applicability (IA)

Inventive step (IS)

Yes: Claims

1-6, 9-12

Claims No:

2. Citations and explanations (Rule 70.7):

see separate sheet

Box No. VI Certain documents cited

1. Certain published documents (Rule 70.10)

and /or

2. Non-written disclosures (Rule 70.9)

see separate sheet

Reference is made to the following documents:

D1: WO 01/81350 A (ASTRAZENECA AB ET AL) 1 November 2001 (2001-11-01)

D2: LEE S C ET AL: "Carbon-carbon linked (pyrazolylphenyl)oxazolidinones with antibacterial activity against multiple drug resistant gram-positive and fastidious gram-negative bacteria" BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 9, no. 12, December 2001 (2001-12), pages 3243-3253, XP002283682

D3: PHILILIPS O A ET AL: "Synthesis and antibacterial activity of 5-substituted oxazolidinones" BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 11, no. 1, 2 January 2003 (2003-01-02), pages 35-41, XP002283683

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claim 8 relates to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

The term "pro-drug" used in claims 7-12 is a functional term, which in the present case is so unclear (Article 6 PCT), even in the light of the description (page 11, line 16, to page 12, line 3), that a meaningful international search with regard to this term is impossible. Consequently, the subject-matter of claim 7 in the whole, and further of claims 8-12 insofar it relates to a "pro-drug", which has not been searched, shall not be the subject of the present opinion, see Rule 66.1 (e) PCT.

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Novelty (Article 33(2) PCT)

The available prior art does not disclose oxazolidinones having the combination of N-HET and T substituents as recited in claim 1 of the present application: the subject-



International application No.

PCT/GB2004/001132

matter of claims 1-6 and 8-12 is therefore novel.

Inventive step (Article 33(3) PCT)

D1, which is considered to represent the closest prior art, describes amongst others antimicrobial 2-oxazolidinones substituted in position 5 by a N-azolylmethyl residue, and substituted in position 3 by a (hetero)aryl radical, itself substituted by a T group, see claims 1 and 12 of D1. The group T may be amongst others an unsaturated 5-membered heteroaryl linked through a carbon atom, like a triazole, pyrazole, isoxazole or isothiazole, see D1, page 8, lines 24-27, and page 27, lines 15-20.

In the light of the teachings of D1, the problem underlying and solved by the present application can be seen in the provision of further antibacterial oxazolidinones.

The solution to this problem proposed in the present application is merely the selection of a combination of meanings of the substituents in position 3 and 5 of the oxazolidinone ring, combination already suggested, but not specifically disclosed, in D1. Such selection does not involve an inventive step in the absence of substantiated surprising resulting effects or properties.

It is moreover noted that such combination is also suggested by the combined teachings of D2 and D3.

The subject-matter of claims 1-6 and 8-12 lacks therefore an inventive step.

Industrial applicability (Article 33(4) PCT)

The compounds, compositions and processes of claims 1-6 and 9-12 can be applied in the pharmaceutical industry.